ahead biotech report thought commerci
wedbush view biotech financi report set begin
come week revisit setup commerci coverag includ
outperform-r dova neutral-r overal
report typic repres period strength sector
cover name rais estim dova begin
doptelet itp launch anticip in-lin print final anticip
unev quarter investor focus inbrija launch progress
pleas see separ report ahead compani
futurecast portfolio review event
continu think unfold ultomiri soliri launch provid
momentum rais total revenu estim company-
seen continu multipl compress peer group trade
consensu earn continu see franchis provid top-
line growth ahead peer vs mean compound-annual-growth-rate
dova outperform new target anticip modest quarter itp
launch kick continu hold posit outlook unfold itp
launch although impact like manifest latter part year
doptelet cld revenu estim remain unchang consensu
howev moder itp estim bottom line
continu see itp launch long-term growth driver laps
partial discount period target move
neutral new target anticip unev quarter
base recent script trend data make minor adjust
revenu assumpt anticip mix print lower valuat
multipl ep move target
although continu await top-lin vumer readout head-to-
head studi versu tecfidera prior data suggest potenti differenti
gi toler think news unlik provid materi boost
share point
neutral new target inbrija ramp still like take time unfold
symphonyhealth script data show limit prescrib uptak
consist launch stage prior manag commentari
recal manag implement sampl program april-may
consensu
respect ampyra provid off-set increas estim
consensu inbrija launch like take time ramp
catalyst remain limit discount rate move
adequ reflect risk net chang lower target
remain neutral rate
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
wedbush view biotech financi report set begin come week
revisit setup commerci coverag includ outperform-r
dova neutral-r overal report typic repres period
strength term potenti earn beat large-cap space pleas see
separ report ahead compani futurecast portfolio
note earn releas
note bmo market open market close tbd determin
set stage look back report reexamin nbi perform four-
week increment around typic report period sinc begin shown
tabl overal return period essenti flat averag chang
contrast weaker perform report mean
perform lag fundament appear solid biotech sector seen
limit perform ytd basi compar sector exampl nbi
post ytd return major perform result
contrast sector industri space lag even within
healthcar group biotech perform fallen short subsector evidenc
subsector comparison see figur
note price qtd quarter date ytd year date
look ahead remaind think fundament biotech sector overal
appear strong notabl valuat across large-cap mid-cap group pull back
prior high compani trade consensu revenu
addit large-cap biotech group continu trade discount
gap widen past quarter see figur
note price
recent acquisit serv remind ever-pres theme continu
see need mid-/late-stag compani de-risk asset among name within
coverag point outperform-r dova two exampl
beyond valuat access capit remain strong evidenc continu ipo reach
public market shown figur note ipo biotech sector price
thu far ampl pipelin addit filed/pend deal deal
activ may eclips seen rel prior decad number deal
amount rais exce prior mean annual valu amount rais see
posit dynam sector overal gaug investor sentiment toward
company-specif outlook herein review company-specif outlook four
commercial-stag compani within coverag univers dova pleas
see separ report ahead compani futurecast
outperform new target anticip slight beat report
financi result market open ahead report moder
strensiq kanuma revenu estim remaind see tabl
combin estim still within guid rang addit
rais soliris/ultomiri estim ahead consensu consensu
repres q/q chang think continu gmg launch
ultomiri roll-out provid momentum histor growth soliri franchis
 deal rais raisedno deal
note product consensu obtain bloomberg total revenu ep estim thomson reuter
complement franchis estim company-sponsor consensu
figur summar current financi guidanc provid last earn
report note pre-exist consensu total revenu slightli ahead
guid rang see non-gaap ep toward high end rang
figur current guidanc report
recent multipl compress occur sector take opportun lower
valuat multipl appli net model chang appli
multipl previous non-gaap ep estim discount back
per year yield new target previous rel large-cap biotech
in-lin peer group trade consensu ep continu hold
outperform rate share risk clinical/regulatori commerci competit
dova outperform new target await itp growth lever dova formal
schedul earn date howev base prior histori anticip releas august
itp approv arriv end june impact doptelet
quarter revenu deriv cld indic recal prior physician survey
gastroenterologists/hepatologist suggest doptelet market share could increas
thu chang revenu estim remain current
consensu look ahead anticip itp launch re-pric provid use
growth lever long-term doptelet howev lower itp
inaugur revenu see model total revenu
note product consensu obtain bloomberg total revenu ep estim thomson reuter
recal assign credit cld itp chemotherapy-induc thrombocytopenia
indic stay consist valuat methodolog use sum-of-part dcf
analysi laps partial discount period target move previous
overal continu hold posit outlook dova near-term roll-out
itp provid new growth driver think pivot data repres anoth
opportun fulli captur market remain outperform rate dova
neutral new target anticip unev quarter report
financi result bmo overal examin current script trend data
consensu estim make minor adjust estim assum in-lin
quarter head-to-head pivot vumer data versu tecfidera remain
readout event could arriv earn updat howev sens limit expect
opportun even data demonstr meaning differenti gi
toler unclear whether materi driver share point
model updat note symphonyhealth data show tecfidera trx count track
q/q growth appear greater growth competitor aubagio
gilenya second quarter strong period growth us tecfidera revenu
q/q growth pair dynam increas
us tecfidera revenu estim q/q bring overal
tecfidera estim consensu estim remain unchang
see tabl summari
note product consensu obtain bloomberg except tysabri total revenu ep estim
nightstar transact complet anticip forthcom guidanc updat
manag figur illustr current guidanc framework
note capit expenditur previous anticip rang
step back continu see challeng posit unlik near-
term clariti tecfidera patent front investor highli focus capit alloc
potenti lack thereof amidst recent multipl compress
sector lower valuat multipl appli
non-gaap ep estim discount back per year off-set laps partial
discount period deriv target share remain neutral rate
neutral new target continu see inbrija launch unfold modest pace
report financi result thursday market close current
script trend data suggest may modest inflect number physician write
script inbrija remain limit trajectori manag implement patient
assist program sampl like interfer provid incomplet pictur see
figur
first figur blue bar correspond trx dollar week orang line
number prescript dispens versu weekli prescrib count number uniqu
prescrib wrote least one prescript week wrx latter figur
prescrib begin expand usag drug would look see count increas
use patient may-jun wrx count increas averag
weekli count increas encourag see breadth inbrija
prescrib steadili increas think prescrib depth also import monitor
note week end holiday week memori day
script data may accur reflect real dynam maintain
inbrija revenu assumpt consensu
respect see figur
note product consensu obtain bloomberg total revenu ep estim thomson reuter
note ampyra script trend continu show strength dollar fall
versu prior quarter captur rate variabl point ampyra current
ampyra consensu impli q/q chang versu thu increas
ampyra revenu estim consensu see figur
recal manag provid product revenu guidanc point inbrija launch
remain earli stage non-gaap sg expens anticip rang
respect
limit near-term catalyst modest inbrija uptak thu far adjust
discount rate consist discount rate singl
product compani appropri reflect risk launch stay otherwis
consist valuat methodolog net chang yield new target see
figur given share current trade limit near-term catalyst event
continu hold neutral rate share
price-to-earnings methodologyearn rate price statement good sold gross sg total oper oper profit invest interest incom total non-operating non- pre-tax incom incom tax effect tax rate net incom net net incom basic weight averag common dilut weight average common share dilut weight average common share basic ep dilut ep basic ep dilut ep
sum-of-part npv methodologypric doptelet doptelet inc dova laura chico phd phone email statement revenue- good sold gross profit- sg total oper oper profit interest incom incom expens interest expens incom total non-operating non- pre-tax incom incom tax expense- effect tax rate net incom basic weight averag common dilut weight average common basic ep dilut ep
price-to-earnings methodologyearn rate price statement good sold gross sg amort acquir intang assets- restructur charges- loss fair valu remeasur conting consideration- collabor profit loss total oper oper profit incom total non-operating non- pre-tax incom incom tax effect tax rate adjust attribut control non- net incom net net incom basic weight averag common dilut weight averag common basic ep dilut ep basic ep dilut ep
sum-of-part npv methodologypric inbrija inbrija ex-u royalty-net incom statement sales/licens gross sg asset impairment- chang fair valu conting consideration- amort intang acquisition-rel costs- total oper oper profit incom total non-operating non- pre-tax incom incom tax effect tax rate net incom net net incom basic weight averag common dilut weight average common share dilut weight average common share basic ep dilut ep basic ep dilut ep risk attain price rate biotechnolog
risk achiev price target includ advers polit event better worse-than expect clinic data
under-perform outperform rate respect
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
juli
juli
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
